Opko Health

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.
  • TickerOPK
  • ISINUS68375N1037
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Jonathan Moreland

InsiderInsights Daily Ratings Report: March 8, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: February 22, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: March 8, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: February 22, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: December 29, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

MarketLine Department

Quest Diagnostics Incorporated - Strategy, SWOT and Corporate Finance Report

Summary Quest Diagnostics Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Quest Diagnostics Incorporated (Quest or 'the company') provides diagnostic information services. The company offers diagnostic testing service and clinical trials testing service to physicians and patients through its laboratories and its patient service centers. It also prov...

Thanks to a better fundamental star rating, OPKO HEALTH sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to OPKO HEALTH (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date January 8, 2021, the closing price was USD 4.40 and its expected value was estimated at USD 4.27.

40 Stocks for February 2018

This report was originally published on Feb 5, 2018. It followed an abbreviated note that was issued prior to the close on January 31, 2018. Long/Short Model Portfolio Monthly Update: January 31, 2018There are limitations inherent in our theoretical model results, particularly with the fact that such results do not represent actual trading and they may not reflect the impact material economic and market factors might have had on our decision making if we were actually managing client money. Please see additional disclaimers and disclosures at the back of this report.We highlight stocks that d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch